PIASγ expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women

Journal of Clinical Pathology

Volumn 67, Issue 4, 2014, Pages 301-306

  Agboola, Ayodeji ^a   Musa, Adewale ^a   Banjo, Adekumbiola ^a   Ayoade, Babatunde ^a   Deji Agboola, Mopelola ^a   Nolan, Christopher ^b   Rakha, Emad ^b   Ellis, Ian ^b   Green, Andrew ^b  

^a OLABISI ONABANJO UNIVERSITY   (Nigeria)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; DIAGNOSTIC SCREENING; TUMOUR MARKERS;

AFRICAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NIGERIA; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN INHIBITORS OF ACTIVATED STAT; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898831348     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201658     Document Type: Article

References (35)

1. Chung CD, Liao J, Liu B, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997;278:1803-5.
2. Liu B, Liao J, Rao X, et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci U S A 1998;95:10626-31.
3. Rodel B, Tavassoli K, Karsunky H, et al. The zinc finger protein Gfi-1 can enhance STAT3 signaling by interacting with the STAT3 inhibitor PIAS3. EMBO J 2000;19:5845-55.
4. Liao J, Fu Y, Shuai K. Distinct roles of the NH2- and COOH-terminal domains of the protein inhibitor of activated signal transducer and activator of transcription (STAT) 1 (PIAS1) in cytokine-induced PIAS1-Stat1 interaction. Proc Natl Acad Sci U S A 2000;97:5267-72.
5. Sundvall M, Korhonen A, Vaparanta K, et al. Protein inhibitor of activated STAT3 (PIAS3) promotes sumoylation and nuclear sequestration of the intracellular domain of ErbB4. J Biol Chem 2012;287:23216-26.
6. Peng Y, Lee J, Zhu C, et al. A novel role for protein inhibitor of activated STAT (PIAS) proteins in modulating the activity of Zimp7, a novel PIAS-like protein, in androgen receptor-mediated transcription. J Biol Chem 2010;285:11465-75.
7. Dolled-Filhart M, Camp RL, Kowalski DP, et al. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 2003;9:594-600.
8. Roth W, Sustmann C, Kieslinger M, et al. PIASy-deficient mice display modest defects in IFN and Wnt signaling. J Immunol, 2004;173:6189-99.
9. Sachdev S, Bruhn L, Sieber H, et al. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev 2001;15:3088-103.
10. Kawai-Kowase K, Kumar MS, Hoofnagle MH, et al. PIAS1 activates the expression of smooth muscle cell differentiation marker genes by interacting with serum response factor and class I basic helix-loop-helix proteins. Mol Cell Biol 2005;25:8009-23.
11. Sentis S, Le Romancer M, Bianchin C, et al. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol Endocrinol 2005;19:2671-84.
12. Lee J, Beliakoff J, Sun Z. The novel PIAS-like protein hZimp10 is a transcriptional co-activator of the p53 tumor suppressor. Nucleic Acids Res 2007;35:4523-34.
13. Miyauchi Y, Yogosawa S, Honda R, et al. Sumoylation of Mdm2 by protein inhibitor of activated STAT (PIAS) and RanBP2 enzymes. J Biol Chem 2002;277:50131-6.
14. Morris JR, Boutell C, Keppler M, et al. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 2009;462:886-90.
15. Wei J, Costa C, Ding Y, et al. mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. J Natl Cancer Inst 2011;103:1552-6.
16. Cong L, Pakala SB, Ohshiro K, et al. SUMOylation and SUMO-interacting motif (SIM) of metastasis tumor antigen 1 (MTA1) synergistically regulate its transcriptional repressor function. J Biol Chem 2011;286:43793-808.
17. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007;110:876-84.
18. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006;25:5846-53.
19. New Frontiers in Respiratory Control. Proceedings of the XIth Annual Oxford Conference in Modeling and Control of Breathing, Nara, Japan, 23-26 July, 2009. Adv Exp Med Biol 2010;669:1-382.
20. Agboola AJ, Musa AA, Wanangwa N, et al. Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Breast Cancer Res Treat 2012;135:555-69.
21. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067-72.
22. Agboola AO, Banjo AA, Anunobi CC, et al. Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women. ISRN Oncology 2013;2013:675051.
23. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
24. Garcia-Caballero T, Grabau D, Green AR, et al. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology 56:472-80.
25. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res: an official journal of the American Association for Cancer Research 2004;10:5367-74.
26. Coppola D, Parikh V, Boulware D, et al. Substantially reduced expression of PIAS1 is associated with colon cancer development. J Cancer Res Clin Oncol 2009;135:1287-91.
27. Baek SH. A novel link between SUMO modification and cancer metastasis. Cell Cycle 2006;5:1492-5.
28. Foulkes WD, Metcalfe K, Sun P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004;10:2029-34.
29. Brayman MJ, Dharmaraj N, Lagow E, et al. MUC1 expression is repressed by protein inhibitor of activated signal transducer and activator of transcription-y. Mol Endocrinol 2007;21:2725-37.
30. Fanelli MA, Montt-Guevara M, Diblasi AM, et al. P-cadherin and beta-catenin are useful prognostic markers in breast cancer patients; beta-catenin interacts with heat shock protein Hsp27. Cell Stress Chaperones 2008;13:207-20.
31. Lamouille S, Derynck R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 2007;178:437-51.
32. Yeh YY, Chiao CC, Kuo WY, et al. TGF-beta1 increases motility and alphavbeta3 integrin up-regulation via PI3 K, Akt and NF-kappaB-dependent pathway in human chondrosarcoma cells. Biochem Pharmacol 2008;75:1292-301.
33. Wang C, Liu X, Ke Z, et al. Mesangial Medium from IgA Nephropathy Patients Induces Podocyte Epithelial-to-mesenchymal Transition through Activation of the Phosphatidyl Inositol-3-kinase/Akt Signaling Pathway. Cell Physiol Biochem 2012;29:743-52.
34. Bischof O, Schwamborn K, Martin N, et al. The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol Cell 2006;22:783-94.
35. Abdel-Fatah TM, Powe DG, Agboola J, et al. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J Pathol 2010;220:419-34.